Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Sitagliptin Extension in T2DM with Severe Renal Insufficiency
NCT00770081Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoint: Assessment of treatment emergent adverse events at 52 weeks. Started Sep 2008; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00770081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770081.